AVROBIO
IPO News: Filed S-1/A: Avrobio Inc. Launches 4.4mm Share IPO with $16.00 - $18.00 Marketing Range
AVROBIO

NASDAQ: AVRO

Initial Filing Date: 05/25/18

Launch Date: 06/11/18

Price Range: $16.00 - $18.00

Shares Offered (Pre-Shoe, mm): 4.4

Primary Shares (mm): 4.4

Secondary Shares (mm): 0.0

Amount Offered (@ Midpoint) (mm): $75.0

% Secondary: 0.0%

Shares Outstanding (mm): 22.3

Market Value (@ Midpoint) (mm): $379.3

Offering as % of Market Value: 19.8%

Bookrunners: Morgan Stanley | Cowen | Wells Fargo Securities | Wedbush

Major Holders: Atlas Venture Funds | Clarus Life Sciences | SV Life Sciences | Citadel | Cormorant

Description: Avrobio is a Phase 2 clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose.

Note: Emerging Growth Company

 

Reference Links: S-1/A